Inside the NIH’s controversial decision to stop its big remdesivir study
The drug maker Gilead Sciences released a bombshell two weeks ago: A study conducted by a U.S. government agency had found that the company’s experimental drug, remdesivir, was the first treatment shown to have even a small effect against Covid-19.
Behind that ray of hope, though, was one of the toughest quandaries in medicine: how to balance the need to rigorously test a new medicine for safety and effectiveness with the moral imperative to get patients a treatment that works as quickly as possible. At the heart of the decision was a process that was — as is often in the case in clinical trials — by turns secretive and bureaucratic.
Read Original Article: Inside the NIH’s controversial decision to stop its big remdesivir study »
